FRA:6MK • US58933Y1055
The current stock price of 6MK.DE is 102.6 EUR. Today 6MK.DE is down by -0.39%. In the past month the price increased by 1.18%. In the past year, price increased by 15.28%.
ChartMill assigns a technical rating of 9 / 10 to 6MK.DE. When comparing the yearly performance of all stocks, 6MK.DE is one of the better performing stocks in the market, outperforming 80.94% of all stocks.
ChartMill assigns a fundamental rating of 6 / 10 to 6MK.DE. While 6MK.DE has a great profitability rating, there are some minor concerns on its financial health.
On February 3, 2026 6MK.DE reported an EPS of 2.09 and a revenue of 16.40B. The company beat EPS expectations (2.98% surprise) and beat revenue expectations (0.31% surprise).
34 analysts have analysed 6MK.DE and the average price target is 108.2 EUR. This implies a price increase of 5.46% is expected in the next year compared to the current price of 102.6.
For the next year, analysts expect an EPS growth of -41.06% and a revenue growth 2.98% for 6MK.DE
Over the last trailing twelve months 6MK.DE reported a non-GAAP Earnings per Share(EPS) of 7.91. The EPS increased by 20.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 29.63% | ||
| ROA | 14.69% | ||
| ROE | 36.71% | ||
| Debt/Equity | 0.77 |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SNW | SANOFI | 9.38 | 193.005B | ||
| 1SAN | SANOFI | 9.38 | 192.909B | ||
| SAN | SANOFI | 9.37 | 192.885B | ||
| MRK | MERCK KGAA | 14.32 | 52.761B | ||
| UCB | UCB SA | 25.58 | 49.192B | ||
| UNC | UCB SA | 25.58 | 48.413B | ||
| 1BAYN | BAYER AG-REG | 7.67 | 37.921B | ||
| BAYN | BAYER AG-REG | 7.66 | 37.637B | ||
| IPN | IPSEN | 14.35 | 13.477B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 16.55 | 10.03B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 9.725B | ||
| VIRP | VIRBAC SA | 16.44 | 2.932B | ||
| DMP | DERMAPHARM HOLDING SE | 15.3 | 2.046B |
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Frankfurt Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Rahway, New Jersey. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The firm sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
MERCK & CO. INC.
126 East Lincoln Avenue, P.O. Box 2000
Rahway NEW JERSEY US
Employees: 75000
Phone: 19087404000
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Rahway, New Jersey. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The firm sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The company sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
The current stock price of 6MK.DE is 102.6 EUR. The price decreased by -0.39% in the last trading session.
MERCK & CO. INC. (6MK.DE) has a dividend yield of 2.85%. The yearly dividend amount is currently 2.77.
6MK.DE has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
MERCK & CO. INC. (6MK.DE) operates in the Health Care sector and the Pharmaceuticals industry.
You can find the ownership structure of MERCK & CO. INC. (6MK.DE) on the Ownership tab.